Chadi hosts three medical oncologists to break down “near equivalence” for alternative standard-of-care cancer therapies – a new paradigm published in detail in the Journal of Clinical Oncology. Ian Tannock, MD, PhD, Princess Margaret Cancer Center (Canada); Mark Ratain, MD, University of Chicago; and Daniel Goldstein, MD, Rabin Medical Center (Israel), describe what is meant by “near equivalence” and the practice of generating evidence to support global alternative cost-effective treatments.
How do you design and implement studies that show lower drug doses are as effective as the labeled doses and treatment schedules? Does listing drugs at a lower price than comparable drugs impede innovation in a capitalistic society? How do poor control arms make it through regulatory and IRB approvals? How can the oncology world come to terms with “imperfect data” for supporting alternative standard-of-care treatments? These questions and more are answered in this meeting of the minds.
View the publication in the Journal of Clinical Oncology ascopubs.org/doi/full/10.1200/JCO.20.02768
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
